Lilly signs up to $1.3 billion deal with Superluminal Medicines to develop obesity medicinesReuters • 08/14/25
Viking's Oral Obesity Drug Poised To Gain Ground After Eli Lilly's Orforglipron Setback: AnalystBenzinga • 08/13/25
Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (Aug 2025)24/7 Wall Street • 08/12/25
If You'd Invested $1,000 in Eli Lilly (LLY) Stock 5 Years Ago, Here's How Much You'd Have TodayThe Motley Fool • 08/12/25
Can Eli Lilly Keep Up as NVO Eyes First Oral Obesity Pill Approval?Zacks Investment Research • 08/11/25
Lilly (LLY) Reliance on International Sales: What Investors Need to KnowZacks Investment Research • 08/11/25
ETFs in Focus on Eli Lilly's Solid Q2 Earnings, Weak Obesity DataZacks Investment Research • 08/08/25
Sitryx regains rights to SYX-1042 itaconate mimetic for chronic autoimmune and inflammatory diseases from Lilly following portfolio reprioritizationGlobeNewsWire • 08/08/25